Anti-FPRL1/RFP + FPR3 antibody [EPR28515-94],Abcam,AB317815
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IHC-P, ICC/IF
Platform ID
BAB247814079
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophil chemotactic factors (PubMed : 1374236). Binding of FMLP to the receptor causes activation of neutrophils (PubMed : 1374236). This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed : 1374236). The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of pro-inflammatory signals such as LTB4 (leukotriene B4) (PubMed : 9547339). Receptor for the chemokine-like protein FAM19A5, mediating FAM19A5-stimulated macrophage chemotaxis and the inhibitory effect on TNFSF11/RANKL-induced osteoclast differentiation (By similarity). Acts as a receptor for humanin (PubMed : 15465011). See full target information FPR2 Additional targets FPR3
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.